Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 29, 2013

Evotec Expands to East Coast of U.S.

  • Evotec has executed a multi-year lease on a facility designed to expand its compound management services to the east coast of the U.S. The facility, located in Branford, Connecticut, is positioned to support the presence of Evotec’s collaborators. According to the company, it will be modern, cost effective, and scalable for continued growth.

    With this expansion, Evotec hopes the investment into industry leading technologies, specifically aimed at library management, and the access to incremental space will enable it to better support the east coast pharmaceutical and biopharmaceutical industry.

    The facility will be fully operational early Q3 2013 and will complement the existing facility in South San Francisco which will continue to be fully operational and serve existing clients.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »